XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Asset Acquisition (Details) - Xinvento B.V. - USD ($)
$ in Thousands
9 Months Ended
Feb. 27, 2023
Sep. 30, 2023
Asset Acquisition    
Aggregate Payment Upon Achievement Of Development And Commercial Milestones $ 206,000  
Clinical development milestone payments 6,000  
Regulatory approval and commercial milestones milestone payments 125,000  
Sales milestone payments 75,000  
Purchase consideration 5,667  
Cash consideration 4,520  
Holdback, payable on the one-year anniversary of the acquisition 500  
Acquisition related costs $ 647  
Research and development    
Asset Acquisition    
Purchase consideration   $ 5,667